|Dr. Stefan Oschmann||Chairman of Exec. Board and Chief Exec. Officer||5.42M||N/A||60|
|Dr. Marcus Kuhnert||Chief Financial Officer and Member of Exec. Board||3.09M||N/A||49|
|Mr. Walter Galinat||Member of Exec. Board, CEO of Performance Materials and Pres of Performance Materials||1.84M||N/A||61|
|Dr. Kai Beckmann||Chief Admin. Officer and Member of Exec. Board||3.47M||N/A||52|
|Dr. Udit Batra Ph.D.||Member of Exec. Board and Chief Exec. Officer of Life Sciences||2.32M||N/A||46|
MERCK Kommanditgesellschaft auf Aktien provides products in the healthcare, life science, and performance materials sectors worldwide. The company offers prescription medicines to treat colorectal cancer, head and neck tumors, multiple sclerosis, infertility, growth hormone disorders, cardiovascular disorders, diabetes, and thyroid disorders; diagnostics and prescription drugs for allergen immunotherapy; and biosimilars for oncology and inflammatory disorders. It also provides over-the-counter products to relieve muscle, joint, and back pain, as well as cold and headaches; probiotic nutritional supplements; vitamin C; and various products with vitamins, minerals, and nutrients that support womens health during pregnancy, nursing, and menopause under the Neurobion, Bion, Femibion, Floratil, Nasivin, Seven Seas, Apaisyl, Cebion, Sangobion, Kytta, Sedalmerck, Vigantoletten, and Doloneurobion brands. In addition, the company offers life science products and services for use in the discovery, development, and manufacture of chemical and biotechnological origin drugs, as well as in research and application laboratories; and specialty chemicals and functional materials for applications consumer electronics, lighting, photovoltaics, printing technology, coatings, plastics, cosmetics, and food industries. The company has a strategic alliance with Pfizer Inc. to co-develop and co-commercialize the anti-PD-L1 antibody avelumab; an agreement with Bristol-Myers Squibb Company for the co-commercialization of Glucophage, an antidiabetic agent in China; a strategic collaboration and license agreement with Intrexon Corporation to co-develop and co-commercialize CAR-T cancer therapies; and a strategic collaboration with F-star for the development and commercialization of five bispecific immuno-oncology antibodies. The company was founded in 1668 and is headquartered in Darmstadt, Germany. MERCK Kommanditgesellschaft auf Aktien is a subsidiary of E. Merck Kommanditgesellschaft.
Merck Kommanditgesellschaft auf Aktien’s ISS Governance QualityScore as of July 1, 2017 is 10. The pillar scores are Audit: 10; Board: 8; Shareholder Rights: 10; Compensation: 8.